Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody
- 1Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, Utrecht, The Netherlands
- 2Department of Pediatrics, Hieronymus Bosch Hospital, Hertogenbosch, The Netherlands
- 3Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
- Correspondence to:
Dr C K van der Ent
Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, KH 01.419.0, PO Box 85090, 3508 AB Utrecht, The Netherlands; k.vanderent{at}wkz.azu.nl
- Received 30 September 2004
- Accepted 17 January 2005
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.
Footnotes
-
Funding: None.
-
Competing interests: None.









